Among the tumor genes (SI Appendix, Fig. S5A), we note some that have been implicated in mTOR activation (MAP2K6 and IL17RC) or inhibition (GJB3) and were upregulated or downregulated, respectively, in everolimus-adapted (LT) tumors. This evidence concerns the gene MTOR and neoplasm.